{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:47:45Z","timestamp":1791942465841,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,3,1]],"date-time":"2027-03-01T00:00:00Z","timestamp":1803859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,3,1]],"date-time":"2027-03-01T00:00:00Z","timestamp":1803859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005366","name":"Universitetet i Oslo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005366","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003126","name":"Opetus- ja Kulttuuriministeri\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003126","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012446","name":"Akershus Universitetssykehus","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012446","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2027,3]]},"DOI":"10.1016\/j.cca.2026.122893","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:46:34Z","timestamp":1791672394000},"page":"122893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cardiac troponin autoantibodies and cancer therapy-related cardiac dysfunction in breast cancer patients receiving anthracycline treatment: secondary analysis of the PRADA study"],"prefix":"10.1016","volume":"594","author":[{"given":"Helea","family":"Junes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Vinje-Jakobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siri L.","family":"Heck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geeta","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torbj\u00f8rn","family":"Omland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saara","family":"Wittfooth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2026.122893_bb0005","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","article-title":"Anthracycline chemotherapy and cardiotoxicity","volume":"31","author":"McGowan","year":"2017","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"2022","key":"10.1016\/j.cca.2026.122893_bb0010","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1093\/ehjci\/jeac106","volume":"23","author":"Lyon","year":"2022","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"10.1016\/j.cca.2026.122893_bb0015","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jaccao.2023.10.008","article-title":"Impact of the ESC cardio-oncology guidelines biomarker criteria on incidence of cancer therapy\u2013related cardiac dysfunction","volume":"6","author":"Mecinaj","year":"2024","journal-title":"JACC CardioOncology."},{"key":"10.1016\/j.cca.2026.122893_bb0020","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.clon.2019.11.008","article-title":"Dynamic changes in high-sensitivity cardiac troponin I in response to anthracycline-based chemotherapy","volume":"32","author":"Tzolos","year":"2020","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.cca.2026.122893_bb0025","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1007\/s12282-017-0778-8","article-title":"High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients","volume":"24","author":"Kitayama","year":"2017","journal-title":"Breast Cancer"},{"key":"10.1016\/j.cca.2026.122893_bb0030","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1373\/clinchem.2012.194860","article-title":"Epitope specificity and IgG subclass distribution of autoantibodies to cardiac troponin","volume":"59","author":"Savukoski","year":"2013","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cca.2026.122893_bb0035","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1373\/clinchem.2011.179226","article-title":"Troponin-specific autoantibody interference in different cardiac troponin I assay configurations","volume":"58","author":"Savukoski","year":"2012","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cca.2026.122893_bb0040","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jjcc.2016.07.018","article-title":"Anti-troponin antibodies following myocardial infarction","volume":"69","author":"O'Donohoe","year":"2017","journal-title":"J. Cardiol."},{"key":"10.1016\/j.cca.2026.122893_bb0045","doi-asserted-by":"crossref","first-page":"307","DOI":"10.21037\/atm.2017.07.40","article-title":"Anti-cardiac troponin antibodies in clinical human disease: a systematic review","volume":"5","author":"Vilela","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.cca.2026.122893_bb0050","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/clinchem\/hvaf077","article-title":"Exploring the role of cardiac troponin-specific autoantibodies: prolonged cardiac troponin elimination, reduced clearance, and variable interference across 5 commercial assays","volume":"71","author":"Salonen","year":"2025","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cca.2026.122893_bb0055","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/clinchem\/hvaf068","article-title":"Influence of macrotroponin on the 99th percentile threshold in 2 high-sensitivity cardiac troponin assays","volume":"71","author":"Strandkj\u00e6r","year":"2025","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cca.2026.122893_bb0060","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1515\/cclm-2025-0427","article-title":"False-positive cardiac troponin I values due to macrotroponin in healthy athletes after COVID-19","volume":"63","author":"Hammerer-Lercher","year":"2025","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.cca.2026.122893_bb0065","doi-asserted-by":"crossref","DOI":"10.1186\/s40959-025-00314-9","article-title":"Macrotroponin interference and association with cardiotoxicity in patients receiving cardiotoxic breast cancer therapy: a pilot study","volume":"11","author":"Soosaipillai","year":"2025","journal-title":"Cardio-Oncology"},{"key":"10.1016\/j.cca.2026.122893_bb0070","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.cjco.2023.05.010","article-title":"Detection of macrotroponin in patients receiving treatment for breast cancer","volume":"5","author":"Kavsak","year":"2023","journal-title":"CJC Open."},{"key":"10.1016\/j.cca.2026.122893_bb0075","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jaccao.2024.06.002","article-title":"Circulating macrotroponin complexes and their impact on cardiac troponin measurements: potential implications for cardio-oncology","volume":"6","author":"Nardi-Agmon","year":"2024","journal-title":"JACC CardioOncology."},{"key":"10.1016\/j.cca.2026.122893_bb0080","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.cca.2026.122893_bb0085","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1161\/CIRCULATIONAHA.121.054698","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): extended follow-up of a 2\u00d72 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"143","author":"Heck","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2026.122893_bb0090","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1532-429X-15-35","article-title":"Standardized image interpretation and post processing in cardiovascular magnetic resonance: Society for Cardiovascular Magnetic Resonance (SCMR) Board of Trustees Task Force on standardized post processing","volume":"15","author":"Schulz-Menger","year":"2013","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"10.1016\/j.cca.2026.122893_bb0095","first-page":"947","article-title":"Analytic result variation for high-sensitivity cardiac troponin: interpretation and consequences","volume":"39","author":"Kavsak","year":"2023","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.cca.2026.122893_bb0100","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1373\/clinchem.2019.306621","article-title":"Educational recommendations on selected analytical and clinical aspects of natriuretic peptides with a focus on heart failure: a report from the IFCC committee on clinical applications of cardiac bio-markers","volume":"65","author":"Kavsak","year":"2019","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cca.2026.122893_bb0105","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1515\/cclm-2013-0310","article-title":"Autoantibody prevalence with an improved immunoassay for detecting cardiac troponin-specific autoantibodies","volume":"52","author":"Savukoski","year":"2014","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.cca.2026.122893_bb0110","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1093\/eurheartj\/ehn268","article-title":"Absence of auto-antibodies against cardiac troponin I predicts improvement of left ventricular function after acute myocardial infarction","volume":"29","author":"Leuschner","year":"2008","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.cca.2026.122893_bb0115","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1515\/cclm-2013-1044","article-title":"Novel sensitive cardiac troponin I immunoassay free from troponin I-specific autoantibody interference","volume":"52","author":"Savukoski","year":"2014","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.cca.2026.122893_bb0120","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1016\/j.jacc.2014.01.073","article-title":"Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review","volume":"63","author":"Thavendiranathan","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.cca.2026.122893_bb0125","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamacardio.2019.2952","article-title":"Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis","volume":"4","author":"Oikonomou","year":"2019","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.cca.2026.122893_bb0130","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ejhf.1494","article-title":"On behalf of the heart failure Association of the European Society of cardiology, heart failure Association of the European Society of cardiology practical guidance on the use of natriuretic peptide concentrations","volume":"21","author":"Mueller","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.cca.2026.122893_bb0135","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1515\/cclm-2021-0626","article-title":"Identification of macrotroponin T: findings from a case report and non-reproducible troponin T results","volume":"59","author":"Lam","year":"2021","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.cca.2026.122893_bb0140","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.jacc.2025.12.078","article-title":"The cTnI\/cTnT ratio in myocardial injury: a multicohort and experimental synthesis","volume":"87","author":"Zimmermann","year":"2026","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.cca.2026.122893_bb0145","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1161\/CIRCULATIONAHA.125.076296","article-title":"Troponin autoantibodies, macrotroponin, and assay interference","volume":"152","author":"Wittfooth","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2026.122893_bb0150","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/nm955","article-title":"Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice","volume":"9","author":"Okazaki","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.cca.2026.122893_bb0155","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.122.010347","article-title":"Cardiac autoantibodies against cardiac troponin I in post-myocardial infarction heart failure: evaluation in a novel murine model and applications in therapeutics","volume":"16","author":"Furusawa","year":"2023","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.cca.2026.122893_bb0160","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1373\/clinchem.2008.115469","article-title":"Autoantibodies to cardiac troponin associate with higher initial concentrations and longer release of troponin I in acute coronary syndrome patients","volume":"55","author":"Pettersson","year":"2009","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cca.2026.122893_bb0165","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.cca.2010.08.005","article-title":"Autoantibodies to cardiac troponin in acute coronary syndromes","volume":"411","author":"Lindahl","year":"2010","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cca.2026.122893_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clinbiochem.2019.11.012","article-title":"Emerging biomarkers for cardiac arrhythmias","volume":"75","author":"Hammerer-Lercher","year":"2020","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.cca.2026.122893_bb0175","series-title":"Encyclopedia of Life Sciences","article-title":"Immune responses: Primary and secondary","author":"demokun","year":"2010"},{"key":"10.1016\/j.cca.2026.122893_bb0180","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1455602","article-title":"Autoantibodies in cancer: a systematic review of their clinical role in the most prevalent cancers","volume":"15","author":"Montero-Calle","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cca.2026.122893_bb0185","article-title":"Chemotherapy-induced, broadly reactive autoantibodies in a colon cancer patient","volume":"14","author":"Broecker","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.cca.2026.122893_bb0190","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s13046-023-02876-x","article-title":"Differential immunomodulatory effects of epirubicin\/cyclophosphamide and docetaxel in breast cancer patients","volume":"42","author":"Wimmer","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126020759?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126020759?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:28:43Z","timestamp":1791941323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898126020759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,3]]},"references-count":38,"alternative-id":["S0009898126020759"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2026.122893","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2027,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiac troponin autoantibodies and cancer therapy-related cardiac dysfunction in breast cancer patients receiving anthracycline treatment: secondary analysis of the PRADA study","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2026.122893","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"122893"}}